Product Overview

HapOnco^® CorePanel™ NGS Assays detect the entire protein-coding region of 136 critical genes related to lung, gastrointestinal, hepatobiliary and pancreatic, urological, gynecologic and breast cancers, including all NCCN/CSCO guidelines-recommended targetable genes such as EGFR, ALK and ROS1, 12 common cancer-causing fusion genes, 18 IO therapy-related genes and 51 hereditary risk-related genes for evaluating hereditary cancers and syndromes. In addition, HapOnco^® CorePanel™ also includes 317 SNP loci associated with chemotherapy responses and side effects. HapOnco^® CorePanel™ can guide therapy selection and provide molecular subtyping, prognostic information, as well as hereditary cancer risk assessment to identify high-risk individuals and families who may benefit from preventive intervention.